Exact Mass: 455.09675000000004

Exact Mass Matches: 455.09675000000004

Found 21 metabolites which its exact mass value is equals to given mass value 455.09675000000004, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Clevidipine

Methyl 5-{[(butanoyloxy)methoxy]carbonyl}-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylic acid

C21H23Cl2NO6 (455.0902358)


C - Cardiovascular system > C08 - Calcium channel blockers > C08C - Selective calcium channel blockers with mainly vascular effects > C08CA - Dihydropyridine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   

5-O-(Butanoyloxymethyl) 3-O-methyl (4R)-4-(2,3-dichlorophenyl)-2,6-dimethyl-3,4-dihydropyridine-3,5-dicarboxylate

5-O-(Butanoyloxymethyl) 3-O-methyl (4R)-4-(2,3-dichlorophenyl)-2,6-dimethyl-3,4-dihydropyridine-3,5-dicarboxylic acid

C21H23Cl2NO6 (455.0902358)


   

sporidesmin F

sporidesmin F

C19H22ClN3O6S (455.0917782000001)


   

Clevidipine

Cleviprex (Clevidipine)

C21H23Cl2NO6 (455.0902358)


C - Cardiovascular system > C08 - Calcium channel blockers > C08C - Selective calcium channel blockers with mainly vascular effects > C08CA - Dihydropyridine derivatives C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker D002317 - Cardiovascular Agents > D002121 - Calcium Channel Blockers D000077264 - Calcium-Regulating Hormones and Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker

   

Cys Cys Cys Gln

(2S)-2-[(2R)-2-[(2R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-sulfanylpropanamido]-3-sulfanylpropanamido]-4-carbamoylbutanoic acid

C14H25N5O6S3 (455.096691)


   

Cys Cys Gln Cys

(2R)-2-[(2S)-2-[(2R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-sulfanylpropanamido]-4-carbamoylbutanamido]-3-sulfanylpropanoic acid

C14H25N5O6S3 (455.096691)


   

Cys Gln Cys Cys

(2R)-2-[(2R)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-4-carbamoylbutanamido]-3-sulfanylpropanamido]-3-sulfanylpropanoic acid

C14H25N5O6S3 (455.096691)


   

Gln Cys Cys Cys

(2R)-2-[(2R)-2-[(2R)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-sulfanylpropanamido]-3-sulfanylpropanamido]-3-sulfanylpropanoic acid

C14H25N5O6S3 (455.096691)


   

Abt-639

Abt-639

C20H20ClF2N3O3S (455.08819040000003)


C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C333 - Calcium Channel Blocker C78272 - Agent Affecting Nervous System > C245 - Anesthetic Agent C78272 - Agent Affecting Nervous System > C241 - Analgesic Agent C93038 - Cation Channel Blocker

   

N-(2-((4aR,6S,8aR)-2-Amino-6-methyl-4a,5,6,8-tetrahydro-4H-pyrano(3,4-d)(1,3)thiazin-8a-yl)thiazol-4-yl)-5-(difluoromethoxy)pyridine-2-carboxamide

N-(2-((4aR,6S,8aR)-2-Amino-6-methyl-4a,5,6,8-tetrahydro-4H-pyrano(3,4-d)(1,3)thiazin-8a-yl)thiazol-4-yl)-5-(difluoromethoxy)pyridine-2-carboxamide

C18H19F2N5O3S2 (455.08973280000004)


   

CID 122706562

CID 122706562

C17H20N4O9P-2 (455.096786)


   

4-tert-butyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]benzenesulfonamide

4-tert-butyl-N-[4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)phenyl]benzenesulfonamide

C19H19F6NO3S (455.0989776)


   

3,4-dimethoxy-N-[4-(2,2,3,3-tetrafluoropropoxy)-3-(trifluoromethyl)phenyl]benzamide

3,4-dimethoxy-N-[4-(2,2,3,3-tetrafluoropropoxy)-3-(trifluoromethyl)phenyl]benzamide

C19H16F7NO4 (455.09675000000004)


   

Succinyl-4-phosphopantetheine

Succinyl-4-phosphopantetheine

C15H24N2O10PS-3 (455.08892340000006)


   

[(2R,3S,4S)-5-(7,8-dimethyl-2-oxido-4-oxo-3,5-dihydrobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] phosphate

[(2R,3S,4S)-5-(7,8-dimethyl-2-oxido-4-oxo-3,5-dihydrobenzo[g]pteridin-10-yl)-2,3,4-trihydroxypentyl] phosphate

C17H20N4O9P-3 (455.096786)


   

FMNH2(3-)

FMNH2(3-)

C17H20N4O9P (455.096786)


A organophosphate oxoanion obtained by deprotonation of the phosphate OH groups as well as position N1 of FMNH2.

   

26-(1,2-dihydroxyethyl)-4,24-dihydroxy-25-oxa-16-azahexacyclo[15.7.2.0¹,²⁶.0²,¹⁵.0⁵,¹⁴.0⁷,¹²]hexacosa-2,4,7,9,11,14,20-heptaen-18,22-diyne-6,13-dione

26-(1,2-dihydroxyethyl)-4,24-dihydroxy-25-oxa-16-azahexacyclo[15.7.2.0¹,²⁶.0²,¹⁵.0⁵,¹⁴.0⁷,¹²]hexacosa-2,4,7,9,11,14,20-heptaen-18,22-diyne-6,13-dione

C26H17NO7 (455.1004972)


   

4-(hydroxymethyl)-2-nitrosophenol; bis(4-hydroxy-3-nitrosobenzaldehyde)

4-(hydroxymethyl)-2-nitrosophenol; bis(4-hydroxy-3-nitrosobenzaldehyde)

C21H17N3O9 (455.0964752)


   

(1s,17s,24r,26r)-26-[(1r)-1,2-dihydroxyethyl]-4,24-dihydroxy-25-oxa-16-azahexacyclo[15.7.2.0¹,²⁶.0²,¹⁵.0⁵,¹⁴.0⁷,¹²]hexacosa-2,4,7,9,11,14,20-heptaen-18,22-diyne-6,13-dione

(1s,17s,24r,26r)-26-[(1r)-1,2-dihydroxyethyl]-4,24-dihydroxy-25-oxa-16-azahexacyclo[15.7.2.0¹,²⁶.0²,¹⁵.0⁵,¹⁴.0⁷,¹²]hexacosa-2,4,7,9,11,14,20-heptaen-18,22-diyne-6,13-dione

C26H17NO7 (455.1004972)


   

4,11,24-trihydroxy-26-(1-hydroxyethyl)-25-oxa-16-azahexacyclo[15.7.2.0¹,²⁶.0²,¹⁵.0⁵,¹⁴.0⁷,¹²]hexacosa-2,4,7,9,11,14,20-heptaen-18,22-diyne-6,13-dione

4,11,24-trihydroxy-26-(1-hydroxyethyl)-25-oxa-16-azahexacyclo[15.7.2.0¹,²⁶.0²,¹⁵.0⁵,¹⁴.0⁷,¹²]hexacosa-2,4,7,9,11,14,20-heptaen-18,22-diyne-6,13-dione

C26H17NO7 (455.1004972)


   

(1s,17s,24r,26r)-4,11,24-trihydroxy-26-[(1r)-1-hydroxyethyl]-25-oxa-16-azahexacyclo[15.7.2.0¹,²⁶.0²,¹⁵.0⁵,¹⁴.0⁷,¹²]hexacosa-2,4,7,9,11,14,20-heptaen-18,22-diyne-6,13-dione

(1s,17s,24r,26r)-4,11,24-trihydroxy-26-[(1r)-1-hydroxyethyl]-25-oxa-16-azahexacyclo[15.7.2.0¹,²⁶.0²,¹⁵.0⁵,¹⁴.0⁷,¹²]hexacosa-2,4,7,9,11,14,20-heptaen-18,22-diyne-6,13-dione

C26H17NO7 (455.1004972)